Clinical trial · Interventional
Study of CEP-701 in Treatment of Prostate Cancer
An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen
NCT00081601CI-TRIAL-00007885completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CEP-701 | Drug | Lestaurtinib | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * at least 18 yrs of age * diagnosis of adenocarcinoma of the prostate * no detectable metastatic disease as assessed by bone and CT scans * has increasing serum PSA concentrations * life expectancy of at least 3 months * ECOG of 0 or 1 * has been withdrawn from antiandrogen therapy for at least 6 weeks prior to entering screening period Exclusion Criteria: * has asymptomatic disease * has active GI ulceration or bleeding * has been treated with non-hormonal systemic anticancer therapy or has received radiation within 4 weeks of baseline visit * bilirubin \>2x ULN or ALT or AST \>2xULN or serum creatinine \>1.5mg/dL * hemoglobin \<9g/dL or platelets below 100,000/uL or ANC below 1500/uL * receiving treatment for HIV with protease inhibitors * has had prior malignancy within past 5 yrs with exception of resected basal or squamous cell carcinomas of the skin * has used investigational drug with previous one month
References
Publications (0)
Data not yet available
No reference posted for this study.